Introduction {#sec0001}
============

Viscosupplementation (VS) of the synovial fluid by intra-articular (IA) injections of hyaluronic acid (HA) is a well-known symptomatic treatment of knee osteoarthritis (OA), in use for more than 30 years. Typically, the treatment consisted of 3 to 5 injections at 1-week intervals, but more recently---in the past 10 to 15 years---alternative regimens have been proposed, consisting of 1 injection only. The question therefore arises whether a single injection (ie, monoinjection) of IA HA has the same level of efficacy as multi-injection regimens, particularly in comparison to injected placebo.

Objectives {#sec0002}
==========

To evaluate the efficacy of a single IA injection of HA, in the symptomatic treatment of knee OA, by comparing clinical results obtained through various trials using the Western Ontario and MacMaster universities pain subscore (WOMAC A), to those obtained with a single injection of placebo.

A meta-analysis of published studies was performed, to collect the largest quantity of clinical results. No systematic review was anticipated.

Methods {#sec0003}
=======

The methods were adapted from the preferred reporting items for systematic reviews and meta-analyses statement[@bib0001] recommendations.

Protocol and ethic statements {#sec0004}
-----------------------------

The protocol was to extract and explore all data results for the WOMAC A, from published studies without limiting the investigation to randomized controlled trials (RCTs). Consequently, with inclusion of all types of study, a high level of evidence is not claimed for this meta-analysis, and no registration was needed. Institutional review board/ethics committee approval was not required for this retrospective meta-analysis that was based solely on published statistical results, without need of any individual patient results.

Eligibility criteria {#sec0005}
--------------------

Inclusion of articles was done after passing the following criteria:•Clinical prospective studies on human patients with knee OA, with all designs permitted, from double-blind RCT to open-label single arm studies. Any kind of comparator was allowed, including injected placebo (ie, saline solution), another IA HA (single or multi-injections), or any other alternative treatment (preferably injected). At minimum, a comparison to baseline was required.•At least 1 population arm treated with a single injection of HA, positioned as the product analyzed or as the control.•The WOMAC A---the single criterion used for this meta-analysis---with at least 2 measures made: 1 at inclusion (ie, baseline) and 1 at follow-up.•Known patient profile for each population, with data documented for age, body mass index (BMI), distribution of Kellgren-Lawrence (KL) radiology grades, and OA anteriority to allow the assessment of comparability between groups.•Quantitative results allowing analysis, preferably given as mean, standard deviation (SD) and number of patients, for each measure.•Qualitative results provided as frequency (percentage or population).

Placebo-injected comparators were analyzed similarly, and their results were pooled in various combinations to match the patient profile of each trial. Other comparator arms present in these studies, such as IA steroids, multi-injection HA, or alternative treatments (eg, plasma rich in growth factors), were not considered for this analysis.

Information sources {#sec0006}
-------------------

A systematic research was done to select proper results, all published before end of April 2018. No limitation to the past was set, because single-injection of IA HA is a relatively recent regimen for the VS in knee OA. There was no restriction placed on the country in each study was done, but only articles published in English were considered. Articles were selected among references found in PubMed, Google, Google Scholar, and from recent meta-analyses.[@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012] We used the following key words, sequentially associated, to get limited lists of properly oriented citations: *single, hyaluronic acid, sodium hyaluronate, intra-articular, injection, knee, osteoarthritis, viscosupplementation, cross-linked, G-F 20, Hylan, Synvisc-One, Durolane, NASHA, Monovisc, Gel-200,* and *clinical trial*.

Search and study selection {#sec0007}
--------------------------

A first selection was done after screening the titles and abstracts, then full-text articles were assessed for their eligibility. Special care was taken to eliminate duplicate publications at different levels of the search. Animal or laboratory testing, general articles, reviews, meta-analyses, recommendations (ie, guidelines), or author\'s opinions were also eliminated.

At the end, articles were also not included if they described:•A specific context different from the current practice of VS of knee OA: other joint, surgery context, or other pathology associated;•A multi-injection regimen (more than 1 IA HA injection per treatment);•A clinical trial done with a nonmarket-approved mono-injection IA HA (European Community or United States);•A planned combination of treatments, without use of IA HA alone; or•Insufficient data for the WOMAC A.

Data process {#sec0008}
------------

Data extracted from the articles were taken as published and no question has been addressed to any of the authors. A strong effort was made to include all possible studies; when needed and justified, the standard error (SE) was calculated from the *P* value, or data was measured on the available graphs. No alternative pain assessment was considered to compensate or complete any missing WOMAC A data.

Data were collected and processed using Excel (Microsoft Corp, Redmond, Washington). Interpretation was done following the description made within each study. Data was recorded per study arm either for the IA HA mono-injection or, when present, the injected placebo comparator. These data included the arm size (ie, population), the average patient profile at inclusion (ie, number, sex, age, BMI, OA anteriority), and the WOMAC A subscore (SD) at each observation time from the inclusion to the last control visit. For a comprehensive assessment, all these scores were recalculated on a 0 to 100 scale, and the observation times were classified at months M1 (2--5 weeks), M2 (6--9 weeks), M3 (10--18 weeks), and M6 (22--26 weeks).

Many studies did not have their own IA placebo control arms, so our approach consisted of using the available IA placebo results as an independent database, and subsequently selecting the best placebo comparator for each study by matching the KL profile. Proper matching was controlled with the χ^2^ test and considered as satisfactory if *P* \> 0.05. Each RCT versus placebo kept its own control arm.

Summary measures {#sec0009}
----------------

In the first phase, each individual study and its matching placebo were analyzed. The variations from baseline (or inclusion) were calculated with the SD for each population seen at each visit (M1, M2, M3, and M6). Then, the comparison to placebo was done, calculating the difference of variation from baseline, the pooled SD and SE, the effect size (ES)---which is defined here as Cohen\'s *d*[@bib0013] with the attached 95% CI---and *P* value.

Synthesis of results {#sec0010}
--------------------

In the second phase, different pooling methods were tested. Using MIX 2.0 software (BiostatXL, Frederick, Maryland) (fixed effect, inverse-variance pooling), a synthesis at each visit time was proposed, representing the results as forest plots. The clinical efficacy was therefore assessed for each individual study, from the absolute difference with placebo (relevant or not) and the statistical significance (*P* value). Also, ES = 0.2 was a priori considered small, 0.5 was considered medium, and 0.8 was considered large. Heterogeneity was assessed from funnel plots and from the indexes *I*^2^ and τ^2^.

Additional analysis {#sec0011}
-------------------

In a separate approach, single-injection HAs were pooled per product to form subgroups \>500 patients. Alternatively, they were pooled together into a subgroup called "other IA HA." Intergroup comparisons were performed between each subgroup (product) and its matched placebo group. Finally, a synthesis was done for all single IA HA products. Graphs were made to illustrate these results, representing the score variations from baseline and ES as a function of time that follows the concept of a therapeutic trajectory.[@bib0002]

Risk of bias within or across studies {#sec0012}
-------------------------------------

There was no systematic review of each characteristic of the studies. Our intention was to explore widely existing data, so we included all types of studies. Consequently, factors like the presence of a control arm, the allocation technique, or the quality of the blinding could not apply. To assess the risk of bias, we first used the funnel plots to detect outlying results and potential publication bias, demonstrated by asymmetry of the funnel plot. Then, to limit the risk of selection bias, special care was given to the quality of the placebo matching for each active study arm. In summary, for the included studies, outlying results, other potential bias, heterogeneity assessment results, and other abnormalities were analyzed. This led us to discard several studies that are further detailed in the Results.

Results {#sec0013}
=======

Study selection {#sec0014}
---------------

Study selection results are described by the flow chart ([Figure 1](#fig0001){ref-type="fig"}). The research was initiated via PubMed, proceeded with Google, and subsequently with Google Scholar. As complement, 55 miscellaneous citations (35 abstracts and 20 full-text articles) were added from various sources. A final search of the lists of references generated numerous duplicates that were eliminated during our selection process. A total of 1547 citations were identified. After screening from title and/or abstract and removal of the duplicate publications, 112 full-text articles of interest were assessed for eligibility. Of these, 57 included data for IA HA mono-injection.[@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021], [@bib0022], [@bib0023], [@bib0024], [@bib0025], [@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030], [@bib0031], [@bib0032], [@bib0033], [@bib0034], [@bib0035], [@bib0036], [@bib0037], [@bib0038], [@bib0039], [@bib0040], [@bib0041], [@bib0042], [@bib0043], [@bib0044], [@bib0045], [@bib0046], [@bib0047], [@bib0048], [@bib0049], [@bib0050], [@bib0051], [@bib0052], [@bib0053], [@bib0054], [@bib0055], [@bib0056], [@bib0057], [@bib0058], [@bib0059], [@bib0060], [@bib0061], [@bib0062], [@bib0063], [@bib0064], [@bib0065], [@bib0066], [@bib0067], [@bib0068], [@bib0069], [@bib0070] At the end, 28 studies were included,[@bib0043], [@bib0044], [@bib0045], [@bib0046], [@bib0047], [@bib0048], [@bib0049], [@bib0050], [@bib0051], [@bib0052], [@bib0053], [@bib0054], [@bib0055], [@bib0056], [@bib0057], [@bib0058], [@bib0059], [@bib0060], [@bib0061], [@bib0062], [@bib0063], [@bib0064], [@bib0065], [@bib0066], [@bib0067], [@bib0068], [@bib0069], [@bib0070] whereas 29 studies were removed for 1 or several of the following reasons:•Two studies were in combination with surgery: anterior cruciate ligament reconstruction,[@bib0026] or arthroscopy[@bib0027];•Eight with experimental regimens from a multi-injection product: single-shot,[@bib0026], [@bib0027], [@bib0028] or large shot grouping several syringes,[@bib0029], [@bib0030], [@bib0031] or smaller shot,[@bib0032] or retreatment[@bib0033];•Three nonapproved products for VS in European Community or United States[@bib0016], [@bib0017], [@bib0034];•Seventeen did not include a WOMAC A result[@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021], [@bib0022], [@bib0023], [@bib0024], [@bib0025], [@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030];•Six with missing data: no SD or SE,[@bib0035], [@bib0036], [@bib0037], [@bib0038] no score at inclusion (set at 100% = major bias),[@bib0039] or inappropriate data (population ratio for gain \>15 mm or 40%)[@bib0040]; and•Two had duplicate datasets: the dataset used by Frampton[@bib0041] was the same as that used by Chevalier et al[@bib0043] and the dataset used by Belzile et al[@bib0042] was the same as that used by Hangody et al.[@bib0060]Figure 1Flow chart. EC = European community; IA HA = intra-articular hyaluronic acid; US = United States; VS = viscosupplementation; WOMAC A = Western Ontario and MacMaster Universities pain subscore. \*Thirty-five abstracts and 20 full-text articles.Figure 1

In summary, 25 of the 28 included studies were successively identified from PubMed (19 during the first search), 3 from Google, and none additional from the other sources.

Study characteristics and placebo matching {#sec0015}
------------------------------------------

Among the 28 included studies, 8 were single-arm, observational studies and 20 were RCTs. Of those RCTs, 14 were described as double-blind. In the 6 remaining RCTs,[@bib0049], [@bib0055], [@bib0057], [@bib0059], [@bib0064], [@bib0065] there were numerous differences in treatments (eg the number of injections) and, although it seemed possible to maintain study blinding for the patient, it was unclear whether the assessment was made by a blinded investigator. The comparators within the 20 RCTs were:•IA saline solution (ie, placebo) for 6 studies;[@bib0043], [@bib0051], [@bib0052]^,^[@bib0060], [@bib0061], [@bib0062]•IA autologous preparation for 4 studies:[@bib0056], [@bib0057], [@bib0064], [@bib0065] platelet rich plasma (PRP), plasma rich in growth factors (PRGF), or mesenchymal stem cells (MSC);•IA ozone for 1 study[@bib0064];•IA drug (ie, corticosteroid) for 3 studies[@bib0047], [@bib0049], [@bib0053];•Another IA HA monoinjection for 3 studies, here analyzed as separate arms,[@bib0045], [@bib0046], [@bib0048] or ignored for 2 other experimental, nonapproved products[@bib0045]; and•IA HA multi-injection for 4 studies^.^[@bib0054], [@bib0055], [@bib0059], [@bib0070] To maintain the same number of injections per patient in both trial arms, 1 study used sham injections from empty syringes[@bib0054] and another used IA saline injections.[@bib0070]

In [Table 1](#tbl0001){ref-type="table"}, studies have been organized per subgroups (Synvisc-One \[Sanofi-Aventis, Bridgewater, New Jersey\], Durolane \[Bioventus LLC, Durham, North Carolina\], or other products), allowing intermediate and global syntheses. The active arms were identified from \#1 to \#31. The reference index of each citation is given with the principal author\'s name and later in the document, we attached the year of publication, as given in the citation.Table 1Selected studies and patient profiles.Table 1IDAuthorRCTFollow-up, wkIA HA mono-injectionN per armSex, W%Age (SD), yBMI (SD)KL %Anteriority, yIIIIV1Chevalier, et al[@bib0043]Yes26Synvisc-One[\*](#tb1fn1){ref-type="table-fn"}1247463.6 (12.6)29.1 (4.8)4906.5 (6.4)2Pal, et al[@bib0044]No52Synvisc-One3947257.6 (9.8)27.7 (4.5)5701.4 (2.8)3Petrella, et al[@bib0045]Yes26Synvisc-One325059.0 (12.0)29.0 (3.8)4405.8 (4.7)4Dreiser, et al[@bib0046]Yes26Synvisc-One1476166.6 (10.7)26.3 (2.8)2406.9 (6.7)5Tammachote, et al[@bib0047]Yes26Synvisc-One508662.6 (10.0)26.34414NA6Sun, et al[@bib0048]Yes26Synvisc-One597162.5 (10.0)25.2 (4.2)3405.2 (4.6)7De Campos, et al[@bib0049]Yes26Synvisc-One527561.0 (12.0)30.0 (5.2)3425NA8Kearey, et al[@bib0050]No52Synvisc-One1196660.2 (11.3)30.9 (6.4)5505.3 (6.2)***Subgroup****26****Synvisc-One****977****70****60.8 (9.5)****28.0 (4.0)****47****2****4.0***9Altman, et al[@bib0051]Yes26Durolane[†](#tb1fn2){ref-type="table-fn"}1724662.9 (10)30.3 (5.0)53235.010Arden, et al[@bib0052]Yes6Durolane1085564.5 (15.9)27.2 (5.6)6702.2 (2.2)11Leighton, et al[@bib0053]Yes26Durolane2185161.9 (9.6)28.2 (4.2)6904.7 (5.4)12Zhang, et al[@bib0054]Yes26Durolane1617460.2 (8.1)NA4203.9 (5.3)13Estades-Rubio, et al[@bib0055]Yes26Durolane275252.9 (13.9)30.0 (4.5)1902.1 (1.2)14Louis, et al[@bib0056]Yes13Durolane245448.5 (11.5)27.0 (2.9)NANA8.4 (8.4)15Vaquerizo, et al[@bib0057]Yes48Durolane485464.8 (7.7)31.0 (4.6)4419NA***Subgroup****26****Durolane****758****56****61.6 (8.9)****28.9 (4.2)****55****7****4.4***16Baron, et al[@bib0058]No26Arthrum 75[‡](#tb1fn3){ref-type="table-fn"}2185662.9 (12.6)27.2 (4.3)4604.1 (5.4)17Diraçoglu, et al[@bib0059]Yes26Monovisc[§](#tb1fn4){ref-type="table-fn"}208058.0 (7.0)30.5 (4.9)NANANA18Hangody, et al[@bib0060]Yes26Monovisc1506659.2 (8.6)28.4 (4.5)181NA19Hangody, et al[@bib0060]Yes26Cingal[§](#tb1fn4){ref-type="table-fn"}1496557.5 (8.4)28.9 (4.7)190NA20Strand, et al[@bib0061]Yes13Gel-One[\|\|](#tb1fn5){ref-type="table-fn"}2476060.9 (10.2)28.3 (4.1)530NA21Takamura, et al[@bib0062]No26Gel-One1525861.0 (9.4)NA4400.6 (0.6)22Borras-Verdera, et al[@bib0063]No26Ostenil-Plus[¶](#tb1fn6){ref-type="table-fn"}80NA\> 40NA1000NA23Dreiser, et al[@bib0046]Yes26Ostenil-Plus1437367.1 (9.7)26.4 (2.9)3105.4 (5.4)24Duymus, et al[@bib0064]Yes52Ostenil-Plus349760.3 (9.1)28.4 (3.6)290NA25Lamo-Espinosa, et al[@bib0065]Yes52HyalOne[\#](#tb1fn7){ref-type="table-fn"}103060.3 (4.4)29.6 (3.4)20406.0 (4.4)26Conrozier, et al[@bib0066]No26HappyCross[⁎⁎](#tb1fn8){ref-type="table-fn"}407360.7 (13.9)28.6 (5.0)4325NA27Monet, et al[@bib0067]No28HappyCross536662.6 (12.3)27.5 (5.2)43194.5 (3.0)28Bashaireh, et al[@bib0068]No39Crespine Gel[††](#tb1fn9){ref-type="table-fn"}843755.8 (9.3)30.5 (4.9)561NA29Sun, et al[@bib0048]Yes26Hya-Joint Plus[‡‡](#tb1fn10){ref-type="table-fn"}627762.7 (8.4)24.7 (3.3)3505.4 (4.4)30Tuan, et al[@bib0069]No26Hya-Joint-Plus468065.1 (9.3)24.0 (3.6)410NA31Ha, et al[@bib0070]Yes15Hyruan-One[§§](#tb1fn11){ref-type="table-fn"}1378162.0 (8.6)25.1 (2.9)4304.0 (4.0)***Subgroup****26****other IA HA****1625****65****61.3 (10.0)****27.7 (4.1)****42****2****3.2***Total monoinjectionsAll IA HA33606361.2 (9.6)28.0 (4.1)4733.7[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12]

Characteristics of each average patient profile are given in [Table 1](#tbl0001){ref-type="table"} for the active IA HA monoinjection arms, and in [Table 2](#tbl0002){ref-type="table"} for the injected placebo arms. There were great differences of population size, from 10 to 394 (average 108) per active arm. The follow-up period was from 6 to 52 weeks, with most at 26 weeks. Because we were limited to 26 weeks for the placebo arms, it was not possible to make any longer comparison. Patient profiles were quite homogeneous, in terms of age and BMI, but there was more concern for the KL grades, varying from 0% to 81% grades I and II, with presence of grades IV from 0% to 40%, which is very high. This confirms the choice in the data process session to match in priority the KL profiles for the selection of each placebo arm, and therefore limit the risk of bias for each comparison. For the placebo arms, less population was available, but pooling placebo arms together allowed intermediate profiles, as shown in the second part of [Table 2](#tbl0002){ref-type="table"}. As for the active arms, placebo profiles were homogeneous in terms of age and BMI.Table 2Selected placebo arms and patient profiles.Table 2AuthorFollow-up, wkIA comparatorN per armSex, %Age (SD), yBMI (SD)KL %Anteriority, yIIIIVAltman et al[@bib0051]26Saline1746463.3 (10.0)29.5 (5.0)52266.5Chevalier et al[@bib0043]26Saline1296862.5 (9.2)29.8 (5.7)6015.8 (5.4)Strand et al[@bib0061]13Saline1286060.3 (10.0)28.7 (3.8)490NAArden et al[@bib0052]6Saline1104660.9 (20.5)27.5 (6.1)6403.1 (3.1)Hangody et al[@bib0060]26Saline697458.0 (9.0)29.1 (4.5)200NATakamura et al[@bib0062]26Saline1596262.8 (8.9)NA4200.7 (0.5)**Pooled placebo**A+C26Saline3036663.0 (9.7)29.6 (5.3)55156.2A+A'26Saline2845762.4 (15.0)28.7 (5.4)56165.2A+T26Saline3336363.1 (9.5)30.3 (5.0)47143.7C+S26Saline2576461.4 (9.6)29.2 (4.9)5505.8C+A'26Saline2395861.8 (15.4)28.7 (5.9)6204.6C+T26Saline2886562.7 (9.0)29.8 (5.7)5003.0H+T26Saline2286661.3 (8.9)29.1 (4.5)3600.7A+C+S26Saline2766462.2 (9.8)29.3 (4.9)53116.2C+S+A'26Saline3675961.3 (13.8)28.7 (5.3)5704.6C+S+H26Saline3266660.7 (9.5)29.2 (4.8)4705.8A+C+S+A'26Saline5416061.9 (12.7)29.0 (5.2)5685.4C+S+H+T26Saline4856561.4 (9.3)29.2 (4.8)4603.0C+S+H+T+A'26Saline5956261.3 (12.1)28.8 (5.2)4903.0**A+C+S+H+T+A'26Saline7696261.7 (11.7)29.0 (5.1)5064.1**[^13]

Matching placebo arms versus active arms is illustrated in [Table 3](#tbl0003){ref-type="table"}. KL grade are detailed in numbers of patients for grades I and II, III, and IV. The χ^2^ test was used to generate the *P* value by comparing the profiles, study per study. The significant differences were shown by *P* \< 0.05. A good profile concordance was obtained for 26 of 29 arms; among failures, \#22 was very atypical with 100% grade III, so it was impossible to match. Two arms---\#14 and \#17--- without known KL profile, were allocated to an average placebo based on presumed similar populations. Obviously, the risk of mismatching between any active arm and its placebo exists, and we took care to minimize the bias for the results.Table 3Matching placebo arms to patient Kellgren-Lawrence (KL) profiles.Table 3IA HA mono-injectionIA comparatorStatisticsID\#AuthorNKL\
I--IIKL\
IIIKL\
IVPooled\
placeboNKL\
I--IIKL\
IIIKL\
IVχ^2^*P*\
value1Chevalier et al[@bib0043]12363600C129517814.420.112Pal et al[@bib0044]3941712230C+S25811614111.720.423Petrella et al[@bib0045]3218140C+S\
C+S+A'258\
368116\
156141\
2111\
11.54\
2.350.46\
0.314Dreiser et al[@bib0046]147112350H+T2281478105.74[\*](#tb3fn1){ref-type="table-fn"}0.0175Tammachote et al[@bib0047]5021227A+C+S\
A+C+S+A'432\
541155\
195231\
30146\
461.68\
3.130.43\
0.216Sun et al[@bib0048]5939200C+T28914314515.530.0637De Campos et al[@bib0049]52211813A+T333131157455.510.0648Kearey,et al[@bib0050]11550650C+S25811614110.540.77  ***Subgroup Synvisc-One***[†](#tb3fn2){ref-type="table-fn"}97249545720C+S+H32717115514.740.0939Altman et al[@bib0051]172409240A1743990450.320.8510Arden et al[@bib0052]10833750A'110407000.83[\*](#tb3fn1){ref-type="table-fn"}0.3611Leighton et al[@bib0053]218711470C\
C+A'129\
23951\
9178\
1481\
13.40\
2.420.18\
0.3012Zhang et al[@bib0054]16194670C+S+H32717115512.020.3613Estades-Rubio et al[@bib0055]272250C+T289143145110.10.00614Louis et al[@bib0056]24NANANAA+C3049016846NANA15Vaquerizo et al[@bib0057]4818219A1743990454.600.10  ***Subgroup Durolane***[‡](#tb3fn3){ref-type="table-fn"}73427840749A+C+S\
A+C+S+A'432\
542155\
195231\
30146\
465.75\
1.680.056\
0.4316Baron et al[@bib0058]217118990C+S+H+T\
C+S+H+T+A'486\
596263\
303222\
2921\
10.45\
1.120.80\
0.5717Diraçoglu et al[@bib0059]20NANANAA+C+S43115523146NANA18Hangody et al[@bib0060]150122271H69551400.610.7419Hangody et al[@bib0060]149120290H69551400.02[\*](#tb3fn1){ref-type="table-fn"}0.8920Strand et al[@bib0061]2471151320S128656300.60[\*](#tb3fn1){ref-type="table-fn"}0.4421Takamura et al[@bib0062]15285670T159926700.12[\*](#tb3fn1){ref-type="table-fn"}0.7322Borras-Verdera et al[@bib0063]800800A\
A+A'174\
28439\
7990\
16045\
4557.7\
53.0\< 0.001\
\< 0.00123Dreiser et al[@bib0046]14398450H+T2281478100.65[\*](#tb3fn1){ref-type="table-fn"}0.4224Duymus et al[@bib0064]3424100H69551401.06[\*](#tb3fn1){ref-type="table-fn"}0.3025Lamo-Espinosa et al[@bib0065]10424A1743990453.860.1426Conrozier et al[@bib0066]40131710A1743990451.920.3827Monet et al[@bib0067]53202310A1743990455.060.08028Bashaireh et al[@bib0068]8436471C+S\
C+S+A'258\
368116\
156141\
2111\
10.78\
1.330.68\
0.5129Sun et al[@bib0048]6240220C+T28914314514.740.09330Tuan et al[@bib0069]4627190C+S25811614113.070.2231Ha et al[@bib0070]13778590C+T28914314512.450.29***Subgroup other IA HA***162590067826C+S+H32717115515.730.057All monoinjections33601673154295C+S+H+T\
C+S+H+T+A'486\
596263\
303222\
2921\
12.16[\*](#tb3fn1){ref-type="table-fn"}\
0.02[\*](#tb3fn1){ref-type="table-fn"}0.14\
0.89[^14][^15][^16][^17]

Results of individual studies and synthesis {#sec0016}
-------------------------------------------

Individual results of the placebo comparisons for the WOMAC A are presented in [Figures 2](#fig0002){ref-type="fig"}, [3](#fig0003){ref-type="fig"}, [4](#fig0004){ref-type="fig"}, and [5](#fig0005){ref-type="fig"} as ES in the form of forest plots at M1, M2, M3, and M6, for all studies. The bars represent the 95% CI. Positive results are in favor of the IA HA product. In the tabular details, identification of the study is provided (identifier, author\'s name, and year) along with ES (95% CI). As complement, the percentage of weight for the synthesis and the *P* value are also given.Figure 2Western Ontario and MacMaster Universities pain subscore (WOMAC A). Comparison of intra-articular hyaluronic acid (IA HA) monoinjection versus intra-articular placebo at 1-month follow-up visit (M1).Figure 2Figure 3Western Ontario and MacMaster Universities pain subscore (WOMAC A). Comparison of intra-articular hyaluronic acid (IA HA) monoinjection versus intra-articular placebo at 2-month follow-up visit (M2).Figure 3Figure 4Western Ontario and MacMaster Universities pain subscore (WOMAC A). Comparison of intra-articular hyaluronic acid (IA HA) monoinjection versus intra-articular placebo at 3-month follow-up visit (M3).Figure 4Figure 5Western Ontario and MacMaster Universities pain subscore (WOMAC A). Comparison of intra-articular hyaluronic acid (IA HA) monoinjection versus intra-articular placebo at 6-month follow-up visit (M6).Figure 5

There are important differences between studies, requiring assessment of heterogeneity. This was first done by funnel plots at M1, M2, M3, and M6 ([Figure 6](#fig0006){ref-type="fig"}). Outlying studies, \#15, \#24, and \#28, were clearly identified and their spots are filled in red on the graphs (both funnel plots and forest plots). No important dissymmetry was found in the funnel plots, and the spots distribution seems balanced around the mean (vertical line).Figure 6Funnel plots.Figure 6

The synthetic results given with the forest plots were obtained by inverse variance pooling (fixed effect) with MIX 2.0 software. Other synthetic results given in [Tables 4](#tbl0004){ref-type="table"} and [5](#tbl0005){ref-type="table"} were calculated for each follow-up time at M1, M2, M3, and M6, to complement the mean difference (MD) of the variation to baseline (0--100 scale), and heterogeneity indicators: *I*^2^ is the ratio of the true heterogeneity (moderate at 50% and high at 75%) and τ^2^ a measure of the heterogeneity between studies, here in dimensionless units (low at 0.04, moderate at 0.09, and high at 0.16^3^).Table 4Selected populations and heterogeneity testing.Table 4*Time*N[\*](#tb4fn1){ref-type="table-fn"}Difference of variation to baselineEffect size (95% CI)StatisticsMeanSD*P* value*I*[@bib0002], (%)τ[@bib0002]*Extended analysis (all studies)* M125023.1819.70.17 (0.12--0.22)\<0.0001870.13 M218874.2721.00.21 (0.15--0.28)\<0.0001850.11 M330146.5622.20.30 (0.25--0.35)\<0.0001840.11 M627288.4121.30.39 (0.33--0.44)\<0.0001880.18Limited analysis (less \#15, \#24, \#28) M123842.1319.70.12 (0.07--0.18)0.0001810.09 M218033.1121.10.16 (0.10--0.23)\<0.0001760.06 M328965.7622.20.27 (0.22--0.32)\<0.0001800.09 M625628.2721.40.39 (0.33--0.44)\<0.0001810.11Restricted analysis (less \#4, \#13, \#14, \#15, \#17, \#22, \#24, \#25, \#28) M121272.6519.80.14 (0.08--0.20)\<0.0001750.06 M216983.8621.50.19 (0.12--0.26)\<0.0001710.05 M326056.3622.40.29 (0.23--0.34)\<0.0001740.06 M622968.5921.50.40 (0.34--0.45)\<0.0001780.09[^18]Table 5Subgroup analysis and heterogeneity testing.Table 5TimeN[\*](#tb5fn1){ref-type="table-fn"}Difference of variation to baselineEffect size (95% CI)StatisticsMeanSD*P* value*I*[@bib0002], %τ[@bib0002]Subgroup Synvisc-One[†](#tb5fn2){ref-type="table-fn"} M18433.1019.50.16 (0.07 to 0.25)0.0007790.07 M22061.9720.50.10 (--0.07 to 0.26)0.26720.08 M39625.7122.20.26 (0.17 to 0.34)\<0.0001680.04 M69598.1720.80.39 (0.30 to 0.48)\<0.0001740.07Subgroup Durolane[‡](#tb5fn3){ref-type="table-fn"} (less \#15) M1199--4.4818.8--0.24 (--0.43 to --0.05)0.013NSNS M25251.8722.00.09 (--0.04 to 0.21)0.17550.03 M35695.4622.10.25 (0.14 to 0.36)\<0.0001910.22 M65319.3421.60.43 (0.31 to 0.55)\<0.0001930.32Subgroup other IA HA (less \#24, \#28) M113422.7220.00.14 (0.06 to 0.21)0.0004810.10 M210724.0421.00.19 (0.11 to 0.28)\<0.0001840.09 M313655.9422.40.27 (0.19 to 0.34)\<0.0001790.10 M610727.8221.80.36 (0.28 to 0.44)\<0.0001780.09[^19][^20][^21][^22]

In [Table 4](#tbl0004){ref-type="table"}, the first group of results are those obtained for the extended analysis that combined all studies. The second group presents the limited analysis by removal of the outlying studies (ie, removing \#15, \#24, and \#28). Finally, the restricted analysis is presented by also removing the studies with active arms having \<30 patients and studies with poor KL placebo matching (ie, also removing \#4, \#13, \#14, \#17, \#22, and \#25). This was done to evaluate how the scores changed (MD, ES), and whether heterogeneity could be improved by removal of the most uncertain studies. As evidenced, the results remained stable whilst a visible improvement was noted on both *I*^2^ (reduced by --10% to --12%) and τ^2^ (reduced by --0.05 to --0.09). If the true heterogeneity remains high with *I*^2^ at 71% to 78%, heterogeneity between studies has been clearly shown to an acceptable level.

To summarize, IA HA monoinjections were found to be statistically better than the IA placebo (*P* \< 0.001) at any time, for the symptomatic (pain) treatment of knee OA. The ES reached 0.39 or 0.40 at M6, which is clinically relevant.

Risk of bias {#sec0017}
------------

There were probably risks of bias for several studies that may raise suspicion. First with the outliers:•\#15: In this autologous preparation study (ie, PRGF),[@bib0057] Durolane was used as control and, for the first time in our VS experience, there was absolutely no improvement compared with baseline but rather a slight worsening for the IA HA group (confirmed with graph).•\#24: In this alternative treatment study (autologous PRP preparation or IA ozone),[@bib0064] Ostenil-Plus (TRB Chemedica Ltd, Geneva, Switzerland) was used as control. After an abnormally strong beneficial effect at M1 and M3, the effect was reduced drastically, becoming insignificant at M6, which was surprising.•\#28: In this well-documented open-label study,[@bib0068] a huge placebo effect was seen and, despite being a good match by KL profile, our comparison placebo arm revealed it to be unsuitable. To us, there was no real bias related to the study, but rather a deficit in our available data.

For the restricted analysis, by removing the poorly KL-placebo-matched studies and the lowest populations (\<30 patient/arm), we improved heterogeneity between studies, to confirm a strong average result, unchanged from our extended analysis. We assumed the risk of bias to be acceptable, without incidence on this synthetic result.

Subgroup analyses {#sec0018}
-----------------

Subgroup results are described in [Table 5](#tbl0005){ref-type="table"}. ES obtained at M3 and M6 for the subgroups Synvisc-One and Durolane are close to those described in the limited analysis presented in [Table 4](#tbl0004){ref-type="table"}. Synvisc-One was supported by 8 trial arms and Durolane by 5 trial arms, after removal of \#15. As shown in the forest plots in [Figures 2](#fig0002){ref-type="fig"} through [5](#fig0005){ref-type="fig"}, there are differences between trials results inside each subgroup. This synthesis per subgroup allows us to conclude that these 2 products seem to perform similarly, without 1 being better than the other. At M1 and M2, results are less consistent due to reduced populations and more difficulties finding ideal placebo comparators.

There was some improvement for heterogeneity indicators *I*^2^ and τ^2^, with the subgroup Synvisc-One, but none with the subgroup Durolane.

Discussion {#sec0019}
==========

Crossing methods {#sec0020}
----------------

Two approaches were used to reach the final synthetic result of an ES versus injected placebo for the IA HA administrated in monoinjection.

With the first approach, we had to evaluate ES (95% CI) for each trial and select a suitable placebo arm to match the KL profiles. In a second step, the meta-analysis was performed with MIX 2.0, giving results in ES (95% CI), a forest plot representation, and a synthesis based on the fixed effect method.

With the second global approach, we first pooled the variations from baseline for each subgroup, weighing population size for each trial. Then, after selection of the pooled placebo comparator with matching KL profile, we evaluated ES (95% CI). Although it gave no individual study result for ES, this method allowed us to represent the WOMAC A variations from baseline, graphically as a function of time ([Figure 7](#fig0007){ref-type="fig"}), comparing each subgroup with its placebo. The differences were always significantly in favor of IA HA at any time, from M1 to M6. One can see the importance of the IA placebo effect and its contribution to patient improvement, which has been pointed out by Altman et al,[@bib0010] and Bannuru et al.[@bib0006], [@bib0009], [@bib0011]Figure 7Variation to baseline per subgroup and group. IA HA = intra-articular hyaluronic acid; OA = osteoarthritis. Synvisc-One (Sanofi-Aventis, Bridgewater, New Jersey). Arthrum 75 (Wellchem Pharmaceuticals, Singapore.).Figure 7

Finally, as illustrated with [Figure 8](#fig0008){ref-type="fig"}, differences were not so great between these methods, leading to ES from 0.37 to 0.39 (maximum at M6) in the comparison versus IA placebo. In terms of differences in score variations (MD) for the populations ([Table 4](#tbl0004){ref-type="table"}), we reached MD = 8.27 to 8.59 mm on the 0 to 100 mm scale. This is clinically relevant, being greater than both the minimal clinically important difference (7.5 mm for improvement) and the smallest detectable difference (8.1 mm), as defined by Angst et al.[@bib0071]Figure 8Effect size as time function: Compared weighing methods. IV = inverse variance; WOMAC A = Western Ontario and MacMaster Universities pain subscore; SE = standard error.Figure 8

Summary of evidence {#sec0021}
-------------------

From an evidence-based medicine point of view, our meta-analysis cannot reach level I or II because all study designs have been accepted, from double-blind RCTs to observational open-label studies. Our objective was to query the largest database and be close to real-world evidence. We believe it was a success to have \>4000 patients for this meta-analysis, and therefore a good representation of monoinjection IA HA.

To answer the question about the relative efficacy of IA HA monoinjection compared with multi-injections, we compared our results with those obtained for pain (WOMAC A or/and visual analog scale for pain) in other meta-analyses,[@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006] where most data were obtained from multi-injection regimens:•Bannuru et al[@bib0002] found ES = 0.46 (95% CI, 0.28--0.65) with *I*^2^=75% at M2, and ES = 0.25 (95% CI, 0.15--0.36) with *I*^2^ = 60% at M3.•Rutjes et al[@bib0003] found ES = 0.37 (95% CI, 0.28--0.46) with τ^2^ = 0.09.•Colen et al[@bib0004] found MD = 10.20 mm (95% CI, 4.42--15.97 mm) with *I*^2^ = 92%.•Miller and Block[@bib0005] found SMD = 0.43 (95% CI, 0.36; 0.60) with *I*^2^ = 73% at 4 to 13 weeks and SMD = 0.38 (95% CI, 0.21--0.55) with *I*^2^ = 75% at 14 to 26 weeks.•Bannuru et al[@bib0006] found ES = 0.34 (95% CI, 0.26--0.42).

In terms of ES or SMD, all these results are very close to ours and heterogeneity seems present at a similar level. Differences between products have been studied by Colen et al,[@bib0004] but these results are limited to a few multi-injection products. More recently, Altman et al[@bib0008] assessed ES depending on molecular weight (Mw) and found ES = 0.52 (95% CI, 0.48--0.56) for high Mw (\>3 MDa (MegaDalton (= 1 million Dalton))) and ES = 0.31 (95% CI, 0.20--0.42) for moderate Mw (1.5--3 MDa). Our results in [Table 5](#tbl0005){ref-type="table"} are roughly comparable: a bit smaller with Synvisc-One and Durolane subgroups for the high Mw, and a bit higher with the other IA HA subgroup for the moderate Mw. In other words, we found less difference between high and moderate Mw IA HA products.

In the symptomatic treatment of knee OA with IA HA, the results of monoinjections demonstrate an efficacy similar to the multi-injections in terms of MD, ES (or SMD), and *P* value, when compared with the IA placebo.

Limitations {#sec0022}
-----------

There are many limitations to our analysis, including making post-hoc IA placebo comparisons when no placebo control was available. Data were obtained from multiple studies done in many different countries, with different patient populations and doctors. This creates possibilities for differences unrelated to treatments used, with a risk of bias, especially for individual trials; however, for each synthesis per subgroup or group, each with large population sizes, the results were properly compared and confirmed using multiple different statistical approaches and weighing methods.

Conclusions {#sec0023}
===========

Results of this meta-analysis suggest that the effects of monoinjections of HA produce results similar to multi-injections of IA HA in terms of pain relief in the treatment of knee OA.
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